Josephine Torrente - Aug 26, 2024 Form 4 Insider Report for AGILE THERAPEUTICS INC (AGRX)

Role: Director
Signature: /s/ Geoffrey P. Gilmore, Attorney-in-fact
Stock symbol: AGRX
Transactions as of: Aug 26, 2024
Transactions value $: -$1,500
Form type: 4
Date filed: 8/26/2024, 05:37 PM
Previous filing: Jun 9, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGRX	Common Stock	Disposed to Issuer	-$20	-13	-1.32%	$1.52	974	Aug 26, 2024	Direct	F1
transaction	AGRX	Common Stock	Disposed to Issuer	-$1.48K	-974	-100%	$1.52	0	Aug 26, 2024	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Josephine Torrente is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 13 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $20, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person.
F2	Upon the consummation of the Merger, pursuant to the Merger Agreement, 974 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $1,480, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person.

Content

Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 13 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $20, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person.

Upon the consummation of the Merger, pursuant to the Merger Agreement, 974 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $1,480, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person.